Mass General Brigham Innovation
Overview
Mass General Brigham Innovation is the business development arm of Mass General Brigham, responsible for the worldwide commercial application of the discoveries made by Mass General Brigham's 80,000 employees . It coordinates industrial relationships and IP management across the Mass General Brigham healthcare system . The organization works with medical inventors, investors, entrepreneurs, and industry to shape the future of medicine . Innovation is responsible for industry collaborations, venture investing, licensing, company creation, technology marketing, open innovation alliances, and workforce development .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Sionna | Mar 2024 | Series C | Co-investor |
| Mediar Therapeutics | Mar 2023 | Series A | Co-investor |
| Claris Bio | Jul 2026 | Series B | Co-investor |
| Affinia Therapeutics | Oct 2025 | Series C | Co-investor |
| Nocion Therapeutics | Jan 2026 | Series B Extension | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Mass General Brigham Innovation based?
Mass General Brigham Innovation is headquartered in Somerville, Massachusetts, United States.
When was Mass General Brigham Innovation founded?
Mass General Brigham Innovation was founded in 1994.
How many portfolio companies does Mass General Brigham Innovation have?
Mass General Brigham Innovation has 28 portfolio companies in Caplight's dataset.
What are some companies in Mass General Brigham Innovation's portfolio?
Portfolio companies visible on Caplight include Sionna, Mediar Therapeutics, Claris Bio, Affinia Therapeutics, Nocion Therapeutics.
What was Mass General Brigham Innovation's most recent investment shown here?
Mass General Brigham Innovation's most recent investment in this portfolio sample was in Claris Bio in 2026.
What sectors does Mass General Brigham Innovation focus on?
Mass General Brigham Innovation focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software.
What company stages does Mass General Brigham Innovation focus on?
Mass General Brigham Innovation typically invests at the Early stage.
What is Mass General Brigham Innovation's AUM?
Mass General Brigham Innovation's assets under management are estimated between $250.0M and $500.0M.